| Serum PLGF, (Median, IQR) | Serum PAPP-A, (Median, IQR) | MAP, (Median, IQR) | |||
---|---|---|---|---|---|---|
 | MoM | CON, pg/mL | MoM | CON, mU/L | MoM | mmHg |
PE Groups | ||||||
 Unaffected by PE (n = 3227) | 1.11 (0.79–1.47) | 43.61 (30.71–58.18) | 0.93 (0.67–1.29) | 4074.56 (2764.41–5867.71) | 0.97 (0.90–1.04) | 78.83 (73.50–84.83) |
 PE (n = 43) | 0.61 (0.43–0.87)** | 23.93 (16.76–32.57)** | 0.78 (0.42–1.17)** | 2718.38 (1695.74–4276.59)** | 1.06 (0.99–1.13)** | 88.17 (81.17–93.00)** |
 Early PE (n = 8) | 0.72 (0.49–0.90)** | 25.31 (18.06–32.06)** | 0.49 (0.28–1.15)* | 1853.23 (847.76–3582.42)* | 1.13 (1.10–1.18)** | 96.17 (91.96–100.17)** |
 Late PE (n = 35) | 0.59 (0.41–0.87)** | 23.36 (16.76–33.20)** | 0.83 (0.50–1.17)* | 2932.82 (1900.94–4322.98)** | 1.04 (0.99–1.12)** | 85.33 (80.67–90.50)** |
 PE with SGA (n = 15) | 0.61 (0.25–0.81)** | 22.22 (9.40–29.47)** | 0.54 (0.39–0.94)* | 2216.32 (1226.38–4322.98)* | 1.10 (1.00–1.14)** | 90.67 (82.67–93.00)** |
SGA Groups | ||||||
 Unaffected by SGA (n = 3171) | 1.10 (0.79–1.47) | 43.62 (30.71–58.18) | 0.93 (0.67–1.29) | 4087.87 (2780.29–5863.93) | 0.97 (0.90–1.04) | 78.83 (73.50–85.00) |
 SGA (n = 99) | 0.85 (0.58–1.26)** | 32.50 (22.51–50.17)** | 0.80 (0.49–1.20)** | 3349.51 (2010.72–5188.12)** | 1.01 (0.92–1.09)* | 82.67 (74.29–88.87)* |
 SGA without PE (n = 84) | 0.92 (0.63–1.28)** | 36.59 (24.88–52.87)** | 0.87 (0.52–1.20)* | 3477.51 (2220.13–5284.75)* | 0.98 (0.90–1.07) | 79.93 (73.83–87.83) |